fact that both CD40L and CD70 are costimulators needed
for full activation of T cells . They showed that the
tumor growth slowed down signiﬁcantly when CD40L and
CD70 were coexpressed by the tumor [28, 29]. Therefore,
we speculate that our patient should elicit a strong immune
response against the tumor resulting in a favorable prog-
nosis based upon his overexpression of CD70 and IL-17A.
Like laryngeal SCC, the mainstay treatment for primary
mucosal melanoma in the head and neck region is radical
surgery with or without adjuvant therapy including radia-
tion and chemotherapy. Although radical surgery yields the
best local control, local recurrence occurs frequently . A
42% recurrence rate has been reported by Snow et al. .
Most recurrent cases occur in the nasal cavity . Shah
et al. reported a 64% recurrence rate. However, primary
laryngeal melanoma has a relatively low recurrence rate.
Yet the survival rate of laryngeal melanoma is still low.
The 5-year survival rate is less than 20% due to metastatic
disease [9, 16].
In summary, we report a 53-year-old male patient with a
collision primary laryngeal malignant melanoma and
invasive squamous cell carcinoma of the larynx with IL-
17A and CD70 over-expression. This gene expression may
open the door to the future where individual melanoma
patients will be treated with tailored immunotherapies. In
addition, this gene expression may serve as useful bio-
markers used for early diagnosis and predicting the prog-
nosis. However, more mucosal melanoma case studies with
long-term follow-up are necessary for better understanding
of the function of these genes in order to apply them in the
treatment for mucosal melanomas.
1. Marur S, Forastiere AA. Head and neck cancer: changing epi-
demiology, diagnosis, and treatment. Mayo Clin Proc. 2008;
2. Barnes L. Surgical pathology of the head and neck, 3rd edn.
Informa Healthcare. New York; 2008. pp. 137–160.
3. Chang AE, Karnell LH, Menck HR. The National Cancer Data
Base Report on cutaneous and non cutaneous melanoma. A
summary of 84,836 cases from the past decade. Cancer. 1998;83:
4. Wagner M, Morris CG, Werning JW, et al. Mucosal melanoma of
the head and neck. Am J Clin Oncol. 2008;31:43–8.
5. Wenig BM. Laryngeal mucosal malignant melanoma. A clini-
copathologic, immunohistochemical, and ultrastructural study in
four patients and a review of the article. Cancer. 1995;75:
6. Wang W, Edington HD, Rao UN, et al. Effects of high-dose
IGNa2b on regional lymph node metastases of human melanoma:
modulation of STAT5, Foxp3, and IL-17. Clin Cancer Res.
7. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma.
J Am Acad Dermatol. 2007;56:828–34.
8. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head
and neck. Am J Surg. 1977;134:531–5.
9. Reuter VE, Woodruff JM. Melanoma of the larynx. Laryngo-
10. Terada T, Saeki N, Toh K, et al. Primary malignant melanoma of
the larynx: a case report and review literature. Auris Nasus
11. Kim H, Park CI. Primary malignant laryngeal melanoma: report
of a case with a review of literature. Yonsei Med J. 1982;23:
12. Tomidokoro Y, Hayashi R, Yamasaki M, et al. Simultaneous
squamous cell carcinoma with leimomyosarcoma of the larynx.
Auris Nasus Larynx. 2009;36:239–43.
13. Medina-Banegas A, Osete-Albaladejo JM, Capitan-Guarnizo A,
et al. Double tumor of the larynx: a case report. Eur Arch Oto-
14. Allen AC, Spitz S. Malignant melanoma: a clinicopathological
analysis of the criteria for diagnosis and prognosis. Cancer.
15. Moore ES, Martin H. Melanoma of the upper respiratory tract and
oral cavity. Cancer. 1955;8:1167–76.
16. Amin HM, Petruzzelli GJ, Husain AN, et al. Primary malignant
melanoma of the larynx. Arch Pathol Lab Med. 2001;125:271–3.
17. Morris LG, Wen YH, Nonaka D, et al. Melanocytic marker in
immunohistochemical evaluation of primary mucosal melanoma
of the head and neck. Head Neck. 2008;30:771–5.
18. Muranski P, Boni A, Antony PA, et al. Tumor-speciﬁc Th17-
polarized cells eradicate large established melanoma. Blood.
19. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are
associated with TNF-a production and contribute to the exacer-
bation of inﬂammatory arthritis. J Immunol. 2007;179:7128–36.
20. von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases
Th17 cells in patients with metastatic melanoma. J Transl Med.
21. Cormary C, Gonzalez R, Faye JC, et al. Induction of T-cell
antitumor immunity and protection against tumor growth by
secretion of soluble human CD70 molecules. Cancer Gene Ther.
22. Garley M, Jablonska E, Grabowska SZ, et al. IL-17 family
cytokines in neutrophils of patients with oral epithelial squamous
cell carcinoma. Neoplasma. 2009;56:96–100.
23. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour
incidence and growth. Nature. 2006;442:461–5.
24. Overwijk WW, de Visser KE, Tirion FH, et al. Immunological
and antitumor effects of IL-23 as a cancer vaccine adjuvant.
J Immunol. 2006;176:5213–22.
25. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the
net angiogenic activity and in vivo growth of human non-small
cell lung cancer in SCID mice through promoting CXCR-2-
dependent angiogenesis. J Immunol. 2005;175:6177–89.
26. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory
T cell dynamics and the regulation by IL-2 in the tumor micro-
environment. J Immunol. 2007;178:6730–3.
27. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor
growth through an IL-6-Stat3 signaling pathway. J Exp Med.
28. Cormary C, Hiver E, Mariame
B, et al. Coexpression of CD40L
and CD70 by semiallogenic tumor cells induces anti-tumor
immunity. Cancer Gene Ther. 2005;2:963–72.
29. Couderc B, Zitvogel L, Douin-Echinard V, et al. Enhancement of
antitumor immunity by expression of CD70 (CD27 ligand) or
CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Cancer Gene Ther. 1998;5:163–75.
30. Snow GB, VanDerEsch EP, Van Sloanten EA. Mucosal mela-
nomas of the head and neck. Head Neck Surg. 1978;1:24–30.
Head and Neck Pathol (2010) 4:295–299 299